AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7477146 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive medication alone
Number of subjects: 46
Study 2011406 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (4 mg once acutely, 3 times 4 mg a day for 3 weeks)
Number of subjects: 16
Study 2011406 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (after 3 weeks treatment)
Number of subjects: 16
Study 2011406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7009019 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine hydrochloride (20 mgs twice daily)
Number of subjects: 107
Study 7009019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 31899491 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior Dance (Dance plus education)
Number of subjects: 82
Study 31899491 — intervention group
Group type: COMPARATOR
Intervention: Education alone (control group)
Number of subjects: 82
Study 30389226 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose VWG OIT (1445 mg of wheat protein)
Number of subjects: 46
Study 30389226 — intervention group
Group type: COMPARATOR
Intervention: High-dose VWG OIT (maximum, 2748 mg of wheat protein)
Number of subjects: 46
Study 30389226 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose VWG OIT
Number of subjects: 46
Study 30389226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 28826170 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation Techniques (MT)
Number of subjects: 27
Study 28826170 — intervention group
Group type: COMPARATOR
Intervention: Home Exercise (HE)
Number of subjects: 27
Study 28826170 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MT and HE
Number of subjects: 27
Study 27314172 — intervention group
Group type: EXPERIMENTAL
Intervention: MeDiet + extra‐virgin olive oil (EVOO)
Number of subjects: 351
Study 27314172 — intervention group
Group type: EXPERIMENTAL
Intervention: MeDiet + nuts (walnuts, almonds, and hazelnuts)
Number of subjects: 351
Study 27314172 — intervention group
Group type: COMPARATOR
Intervention: Control low‐fat diet
Number of subjects: 351
Study 25039364 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction therapy with reduced doses of tacrolimus, steroids, and mycophenolate mofetil
Number of subjects: 60
Study 25039364 — intervention group
Group type: COMPARATOR
Intervention: Thymoglobulin in association with standard dose immunosuppression (IS)
Number of subjects: 60
Study 21824444 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg HCA with a high-carbohydrate meal (2 g carbohydrate/kg body weight, 80 % carbohydrate, 8 % fat, 12 % protein)
Number of subjects: 8
Study 21824444 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg HCA with a high-carbohydrate meal
Number of subjects: 8
Study 21824444 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg HCA
Number of subjects: 8
Study 21824444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16973659 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intravitreal triamcinolone (ivTA)
Number of subjects: 63
Study 16973659 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg intravitreal triamcinolone (ivTA)
Number of subjects: 63
Study 16973659 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg intravitreal triamcinolone (ivTA)
Number of subjects: 63
Study 15718403 — intervention group
Group type: EXPERIMENTAL
Intervention: Microgravity (0 G)
Number of subjects: 12
Study 15718403 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypergravity (1.8 G)
Number of subjects: 12
Study 15718403 — intervention group
Group type: COMPARATOR
Intervention: Normal gravity (1 G)
Number of subjects: 12
Study 15718403 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypergravity (1.7 G)
Number of subjects: 12
Study 12111110 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine treatment (25 mg/m² daily for 5 days every 28 days)
Number of subjects: 192
Study 10502181 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced EUS with air-filled albumin (0.22 mL/kg) intravenously injected at a rate of 1 mL/sec for 10 minutes
Number of subjects: 42
Study 10502181 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced EUS
Number of subjects: 42
Study 7560251 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron (0.6 to 5.0 mg/kg)
Number of subjects: 80
Study 7560251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 7560251 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron (doses > or = 3.0 mg/kg)
Number of subjects: 80
Study 7560251 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron
Number of subjects: 80
Study 2080113 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehab group
Number of subjects: 100
Study 2080113 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 436308 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 15
Study 436308 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 15
Study 436308 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (Control)
Number of subjects: 15
Study 31274484 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion (15 mg/kg) started 20 min before induction, during surgery, and for the first postoperative 24 hours.
Number of subjects: 250
Study 31274484 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group).
Number of subjects: 250
Study 31274484 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion (15 mg/kg).
Number of subjects: 250
Study 28599889 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone (7.5 mg kg−1)
Number of subjects: 6
Study 28599889 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (3 mg kg−1)
Number of subjects: 6
Study 28599889 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone (1.5 mg kg−1)
Number of subjects: 6
Study 26595300 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive Writing
Number of subjects: 113
Study 26595300 — intervention group
Group type: COMPARATOR
Intervention: Neutral Writing
Number of subjects: 113
Study 23249429 — intervention group
Group type: EXPERIMENTAL
Intervention: Preload group (vegetable salad, yogurt, and water consumed 15 min before the main meal)
Number of subjects: 60
Study 23249429 — intervention group
Group type: COMPARATOR
Intervention: Control group (vegetable salad, yogurt, and water consumed with meal)
Number of subjects: 60
Study 21261516 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal tea containing fenugreek (Group 1, n=22)
Number of subjects: 66
Study 21261516 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group 2, n=22)
Number of subjects: 66
Study 21261516 — intervention group
Group type: COMPARATOR
Intervention: Control (Group 3, n=22)
Number of subjects: 66
Study 18188496 — intervention group
Group type: EXPERIMENTAL
Intervention: Short latency afferent inhibition (SAI) test in SIVD patients
Number of subjects: 20
Study 18188496 — intervention group
Group type: COMPARATOR
Intervention: Short latency afferent inhibition (SAI) test in control subjects
Number of subjects: 20
Study 16006055 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to an alcohol health worker (AHW) who delivered a brief intervention (n = 287)
Number of subjects: 599
Study 16006055 — intervention group
Group type: COMPARATOR
Intervention: Information only control (n = 312)
Number of subjects: 599
Study 12900677 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (80% of single-repetition maximal lift)
Number of subjects: 42
Study 12900677 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 42
Study 12900677 — intervention group
Group type: COMPARATOR
Intervention: Control (light yoga and breathing exercises)
Number of subjects: 42
Study 10884257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.2 mg/kg)
Number of subjects: 47
Study 10884257 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam (0.3 mg/kg)
Number of subjects: 47
Study 8633935 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) treatment
Number of subjects: 142
Study 8633935 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 142
Study 1533530 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 120 mg
Number of subjects: 0
Study 1533530 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg
Number of subjects: 0
Study 1533530 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine 10 mg
Number of subjects: 0
Study 1533530 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 3880657 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine (0.4 mg/m2/1/day by continuous infusion)
Number of subjects: 99
Study 3880657 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine (1.7 mg/m2/1/day by continuous infusion)
Number of subjects: 99
Study 3880657 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine (1.2 mg/m2/1/day by continuous infusion)
Number of subjects: 99
Study 3880657 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine (1.2 mg/m2/1/day intermittent bolus)
Number of subjects: 99
Study 31877141 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500mg once-daily for 14 days)
Number of subjects: 81
Study 31877141 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (500mg twice-daily for 14 days)
Number of subjects: 81
Study 29511334 — intervention group
Group type: EXPERIMENTAL
Intervention: D-amphetamine (20 mg oral)
Number of subjects: 26
Study 29511334 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine (20 mg oral)
Number of subjects: 26
Study 29511334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 27460616 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood sexual abuse
Number of subjects: 228
Study 27460616 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood emotional abuse
Number of subjects: 228
Study 27460616 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood physical abuse
Number of subjects: 228
Study 25944519 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination 17β-estradiol/progesterone capsule
Number of subjects: 66
Study 25944519 — intervention group
Group type: COMPARATOR
Intervention: Coadministered reference products of estradiol and progesterone
Number of subjects: 66
Study 23455721 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7‐Hz rTMS stimulation at 100 % of the motor cortex excitability threshold on the prefrontal cortex of one randomly assigned hemisphere
Number of subjects: 12
Study 23455721 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS on the left hemisphere
Number of subjects: 12
Study 23455721 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 12
Study 23455721 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS on the right hemisphere
Number of subjects: 12
Study 23455721 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 12
Study 21282560 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 80 mg
Number of subjects: 1291
Study 21282560 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 40 mg
Number of subjects: 1291
Study 21282560 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 320 mg
Number of subjects: 1291
Study 21282560 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan 40 mg
Number of subjects: 1291
Study 20306755 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pressure pneumoperitoneum (7-10 mm Hg)
Number of subjects: 60
Study 20306755 — intervention group
Group type: COMPARATOR
Intervention: Standard pressure pneumoperitoneum (12-14 mm Hg)
Number of subjects: 60
Study 16492849 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed Intermittent Epidural Bolus (PIEB) - 6 mL bolus every 30 min starting 45 min after intrathecal injection
Number of subjects: 126
Study 16492849 — intervention group
Group type: COMPARATOR
Intervention: Continuous Epidural Infusion (CEI) - 12 mL/h infusion starting 15 min after intrathecal injection
Number of subjects: 126
Study 14526630 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention for malignant neoplasms
Number of subjects: 0
Study 11096040 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD) recommendation for men with ESRD
Number of subjects: 271
Study 11096040 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD) recommendation for patients with good compliance
Number of subjects: 271
Study 11096040 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD) recommendation for patients weighing less than 200 lb
Number of subjects: 271
Study 11096040 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD) recommendation for patients with residual renal function
Number of subjects: 271
Study 11096040 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD) recommendation for patients without diabetes
Number of subjects: 271
Study 11096040 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD) recommendation for patients living with family
Number of subjects: 271
Study 11096040 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD) recommendation based on nephrologists' years of practice
Number of subjects: 271
Study 9346148 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Number of subjects: 68
Study 9346148 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia pump
Number of subjects: 68
Study 7818648 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide 1.25 mg
Number of subjects: 16
Study 7818648 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide 5.0 mg
Number of subjects: 16
Study 7818648 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide 1.25 mg and 5.0 mg
Number of subjects: 16
Study 2453895 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (6 mg)
Number of subjects: 6
Study 2453895 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.2 mg)
Number of subjects: 6
Study 2453895 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.2 mg)
Number of subjects: 6
Study 2453895 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3 mg)
Number of subjects: 6
Study 2453895 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.2 mg plus Naloxone 0.2 mg
Number of subjects: 6
Study 2453895 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg plus Naloxone 0.2 mg
Number of subjects: 6
Study 27011262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 0.25 mg/0.01 ml
Number of subjects: 8
Study 27011262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 0.625 mg/0.025 ml
Number of subjects: 8
Study 27011262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 8
Study 27978532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200mg plus paracetamol 325mg TID
Number of subjects: 80
Study 27978532 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400mg TID
Number of subjects: 80
Study 25969894 — intervention group
Group type: EXPERIMENTAL
Intervention: MenABCWY formulations containing OMV components
Number of subjects: 495
Study 25969894 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of OMV‐containing MenABCWY formulations
Number of subjects: 495
Study 25969894 — intervention group
Group type: COMPARATOR
Intervention: MenABCWY or rMenB groups
Number of subjects: 495
Study 25969894 — intervention group
Group type: COMPARATOR
Intervention: MenACWY‐CRM group
Number of subjects: 495
Study 25969894 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 495
Study 24391139 — intervention group
Group type: EXPERIMENTAL
Intervention: F4/AS01(B) booster administered alone
Number of subjects: 2
Study 24391139 — intervention group
Group type: EXPERIMENTAL
Intervention: F4/AS01(B) booster administered after chloroquine (300 mg)
Number of subjects: 2
Study 24391139 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (300 mg) administered 2 days before the booster
Number of subjects: 2
Study 22244384 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Oss Collagen with implant placement (Group 1)
Number of subjects: 25
Study 22244384 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Oss Collagen without implant placement (Group 2)
Number of subjects: 25
Study 22244384 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 3) - untreated sockets
Number of subjects: 25
Study 20385995 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 349
Study 20385995 — intervention group
Group type: EXPERIMENTAL
Intervention: LV5FU2
Number of subjects: 349
Study 20385995 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Number of subjects: 349
Study 18344895 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori positive
Number of subjects: 1790
Study 18344895 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradicated
Number of subjects: 1790
Study 18344895 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of antral intestinal metaplasia (IM)
Number of subjects: 1790
Study 18344895 — intervention group
Group type: COMPARATOR
Intervention: H. pylori eradication
Number of subjects: 1790
Study 15996025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ninjinyoeito (NYT)
Number of subjects: 23
Study 15996025 — intervention group
Group type: COMPARATOR
Intervention: Control group (without NYT)
Number of subjects: 23
Study 12188104 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (6-12 mg/day)
Number of subjects: 0
Study 12188104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10480420 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF-based triple therapy (1.0 g of MMF twice daily from postoperative day 2, n=50)
Number of subjects: 100
Study 10480420 — intervention group
Group type: COMPARATOR
Intervention: Control group (CsA-Neoral and steroids, n=50)
Number of subjects: 100
Study 9168850 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 50, 100, or 250 micrograms
Number of subjects: 342
Study 9168850 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 or 250 micrograms
Number of subjects: 342
Study 9168850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study 7681647 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid antigen detecting test and a 10-day oral penicillin course
Number of subjects: 0
Study 7681647 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid antigen detecting test and intramuscular benzathin penicillin G
Number of subjects: 0
Study 7681647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular benzathin penicillin G for all children with pharyngitis
Number of subjects: 0
Study 7681647 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of group A streptococcal pharyngitis
Number of subjects: 0
Study 2877645 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrasonde
Number of subjects: 36
Study 2877645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff measurements by trained physician assistant (PA)
Number of subjects: 36
Study 2877645 — intervention group
Group type: COMPARATOR
Intervention: Cuff measurements by clinic nurses (casual readings)
Number of subjects: 36
Study 2877645 — intervention group
Group type: COMPARATOR
Intervention: Cuff measurements by clinic nurses (serial readings)
Number of subjects: 36
Study 31747468 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training + GTE (ET + GTE)
Number of subjects: 30
Study 31747468 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training + placebo (ET + P)
Number of subjects: 30
Study 31747468 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise) + placebo
Number of subjects: 30
Study 30031553 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Diagnosis and Therapy (MDT)
Number of subjects: 22
Study 30031553 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT + LUMOback
Number of subjects: 22
Study 30031553 — intervention group
Group type: COMPARATOR
Intervention: MDT
Number of subjects: 22
Study 26288118 — intervention group
Group type: EXPERIMENTAL
Intervention: mirabegron 50 mg/day
Number of subjects: 1987
Study 26288118 — intervention group
Group type: COMPARATOR
Intervention: tolterodine ER 4 mg/day
Number of subjects: 1987
Study 26288118 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1987
Study 24899242 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training program (weekly group-based classes in mindfulness practice, 2 ½ hours, for 8 weeks plus a 7-hour Saturday session in Week 6)
Number of subjects: 150
Study 24899242 — intervention group
Group type: COMPARATOR
Intervention: Standard care (routine total joint arthroplasty)
Number of subjects: 150
Study 24899242 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training program
Number of subjects: 150
Study 22235059 — intervention group
Group type: EXPERIMENTAL
Intervention: Action observation (EG) - watching video footage of daily routine tasks and imitating movements for 2 minutes with therapist assistance.
Number of subjects: 102
Study 22235059 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - static images without animals or human beings and simulated shoulder and elbow joint mobilization activities.
Number of subjects: 102
Study 20397265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) + Pringle maneuver (PM)
Number of subjects: 61
Study 20397265 — intervention group
Group type: COMPARATOR
Intervention: Pringle maneuver (PM) alone
Number of subjects: 61
Study 19558064 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteric feeding via a nasoduodenal tube
Number of subjects: 40
Study 19558064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasoduodenal tube feeding
Number of subjects: 40
Study 19558064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasoduodenal tube placement and confirmation by serial pH monitoring and radiological examination
Number of subjects: 40
Study 15782753 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling about cessation within the past year
Number of subjects: 1941